July 11, 2005 After trading higher all day, the Centient Biotech 200 closed 9 points higher at 3520.90, a rise of .27%. Genentech announced solidly higher revenues and profits after the closing bell, Bayer and Onyx have completed the FDA filings to get their kidney cancer drug approved, NSP did the same for an osteoporosis drug, Able Labs received the FDA list of manufacturing deficiencies that led to a shut-down of all operations, AstraZeneca partnered up with Avanir on a cardiovascular drug, Esprit Pharma has licensed a drug for overactive bladder, Roche will collaborate with GE, using GE PET scanners to track the effectiveness of an Alzheimer’s drug, and Novartis is seeking FDA approval to use Femara for breast cancer immediately after surgery, rather than waiting until after 5 years of tamoxifen therapy. More details...
